Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF. Forero-Torres A, et al. Cancer Biother Radiopharm. 2005 Aug;20(4):379-90. doi: 10.1089/cbr.2005.20.379. Cancer Biother Radiopharm. 2005. PMID: 16114986 Clinical Trial.
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.
Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF. Forero-Torres A, et al. Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035. Clin Breast Cancer. 2010. PMID: 20705559 Free PMC article. Clinical Trial.
Effect of niclosamide on basal-like breast cancers.
Londoño-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, Lobuglio AF, Li Y, Buchsbaum DJ. Londoño-Joshi AI, et al. Mol Cancer Ther. 2014 Apr;13(4):800-11. doi: 10.1158/1535-7163.MCT-13-0555. Epub 2014 Feb 19. Mol Cancer Ther. 2014. PMID: 24552774 Free PMC article.
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A; Translational Breast Cancer Research Consortium (TBCRC). Vaklavas C, et al. Breast Cancer Res. 2020 Feb 18;22(1):22. doi: 10.1186/s13058-020-01258-x. Breast Cancer Res. 2020. PMID: 32070401 Free PMC article. Clinical Trial.
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Forero-Torres A, Infante JR, Waterhouse D, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, von Roemeling R, Greenberg J, Saleh M. Forero-Torres A, et al. Cancer Med. 2013 Dec;2(6):925-32. doi: 10.1002/cam4.137. Epub 2013 Oct 25. Cancer Med. 2013. PMID: 24403266 Free PMC article. Clinical Trial.
128 results